Navigation Links
The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
Date:11/1/2013

WHITE PLAINS, N.Y., Nov. 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is aware of the FDA's decision requesting Ariad Pharmaceuticals to suspend marketing and sales of Iclusig (ponatinib), a therapy for chronic myeloid leukemia (CML).  As suggested by the FDA, LLS encourages all patients currently receiving ponatinib to speak with their physician to discuss the risk and benefits of continuing treatment with the drug.  Those patients who are responding well to ponatinib, and who are not eligible for therapeutic alternatives, may be able to obtain ponatinib on a compassionate use basis, but need to speak with their oncologists immediately.

We are here to advise patients how the recent news applies to them and what discussions to have with their physicians.  Patients can contact LLS's Information Resource Center at 1-800-955-4572, Monday through Friday from 9 a.m. to 6 p.m. ET.

LLS recognizes the need and urgency for new treatments for CML.  In 2013, we committed $1.7 million to CML research ranging from basic science to clinical research on how best to use new therapies.

"The Leukemia & Lymphoma Society exists to find cures and ensure access to treatments for blood cancer patients," said Mark Velleca, MD, PhD, chief policy and advocacy officer for LLS.  "As such, we felt it was important to comment on this important access issue.  Working with CML physicians and other advocacy groups, we have requested that FDA facilitate continued access to ponatinib for certain patients – such as those in blast crisis – for whom interruption of therapy could be extremely detrimental."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
andrea.greif@lls.org

Scott Orstad
(914) 821-8873
Scott.orstad@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
2. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
3. St. Jude Childrens Research Hospital study yields new strategy against high-risk leukemia
4. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
5. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
6. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
9. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
10. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
11. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016  Johnson & Johnson (NYSE: ... Global Healthcare Conference on Tuesday, Feb. 23, at the ... Caruso , Vice President, Finance & Chief Financial Officer ... represent the Company in a session scheduled at 10:00 ... --> www.investor.jnj.com . --> This webcast ...
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... Aesthetic Devices - Medical Devices Pipeline Assessment, ... "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" provides ... This report is prepared using data ... GlobalData,s team of industry experts. *Note: Certain sections ... on the availability and relevance of data in relation ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... The ... been won. A team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), ... the delicate neural circuits of an intact rabbit brain for extremely long-term storage ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, ... the Food & Beverage and Dietary Supplement market segments ... Canada and USA geographies east of the Rocky Mountains since 2012. Consistent ...
(Date:2/8/2016)... ... ... Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of affection ... year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... of the lives they’ve led and the people they’ve touched. , That’s why ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, ... the latest beneficiary of their ongoing community enrichment program. The current campaign fundraises ... schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & ...
Breaking Medicine News(10 mins):